Skip to main content

Table 1 Associations of CK19 expression and presence of MVI with clinicopathological characteristics in patients with HCC

From: Individual and joint influence of cytokeratin 19 and microvascular invasion on the prognosis of patients with hepatocellular carcinoma after hepatectomy

Characteristic CK19(−) CK19(+) P MVI(−) MVI(+) P CK19(−)/MVI(−) CK19(−)/MVI(+) CK19(+)/MVI(−) CK19(+)/MVI(+) P
Age (years) 49.94 ± 10.51 46.76 ± 11.64 0.020 49.59 ± 10.80 48.75 ± 10.91 0.469 50.18 ± 10.48 49.62 ± 10.57 46.71 ± 12.04 46.78 ± 11.52 0.134
Sex
 Male 227 (84.1%) 67 (81.7%) 0.613 151 (81.6%) 143 (85.6%) 0.319 126 (81.8%) 101 (87.1%) 25 (80.6%) 42 (82.4%) 0.654
 Female 43 (15.9%) 15 (18.3%)   34 (18.4%) 24 (14.4%)   28 (18.2%) 15 (12.9%) 6 (19.4%) 9 (17.6%)  
BCLC stage
 0 10 (3.7%) 5 (6.1%) 0.238 12 (6.5%) 3 (1.8%) 0.086 7 (4.5%) 3 (2.6%) 5 (16.1%) 0 (0%) 0.003
 A 181 (67.0%) 60 (73.2%)   122 (65.9%) 119 (71.3%)   105 (68.2%) 76 (65.5%) 17 (54.8%) 43 (84.3%)  
 B 79 (29.3%) 17 (20.7%)   51 (27.6%) 45 (26.9%)   42 (27.3%) 37 (31.9%) 9 (29.0%) 8 (15.7%)  
HBsAg
 Negative 35 (13.0%) 11 (13.4%) 1.000 20 (10.8%) 26 (15.6%) 0.207 16 (10.4%) 19 (16.4%) 4 (12.9%) 7 (13.7%) 0.549
 Positive 235 (87.0%) 71 (86.6%)   165 (89.2%) 141 (84.4%)   138 (89.6%) 97 (83.6%) 27 (87.1%) 44 (86.3%)  
HBV-DNA (IU/ml)
  < 5 × 102 90 (33.3%) 32 (39.0%) 0.356 63 (34.1%) 59 (35.3%) 0.823 51 (33.1%) 39 (33.6%) 12 (38.7%) 20 (39.2%) 0.823
5 × 102 180 (66.7%) 50 (61.0%)   122 (65.9%) 108 (64.7)   103 (66.9%) 77 (66.4%) 19 (61.3%) 31 (60.8%)  
Anti-HCV
 Negative 266 (98.5%) 80 (97.6%) 0.627 182 (98.4%) 164 (98.2%) 1.000 152 (98.7%) 114 (98.3%) 30 (96.8%) 50 (98.0%) 0.896
 Positive 4 (1.5%) 2 (2.4%)   3 (1.6%) 3 (1.8%)   2 (1.3%) 2 (1.7%) 1 (3.2%) 1 (2.0%)  
Tumor diameter (cm) 5.00 (3.50, 7.50) 4.75 (3.5, 8.00) 0.383 4.50 (3.50, 7.00) 5.50 (3.50, 8.50) 0.008 4.75 (3.50, 7.00) 6.00 (3.50, 8.50) 4.00 (2.5, 6.00) 5.00 (3.50, 10.00) 0.017
Tumor number
 1 193 (71.5%) 65 (79.3%) 0.200 140 (75.7%) 118 (70.7%) 0.335 117 (76.0%) 76 (65.5%) 23 (74.2%) 42 (82.4%) 0.098
2 77 (28.5%) 17 (20.7%)   45 (24.3%) 49 (29.3%)   37 (24.0%) 40 (34.5%) 8 (25.8%) 9 (17.6%)  
Tumor envelope
 Complete 230 (85.2%) 66 (80.5%) 0.305 164 (88.6%) 132 (79.0%) 0.019 134 (87.0%) 96 (82.8%) 30 (96.8%) 36 (70.6%) 0.008
 Incomplete 40 (14.8%) 16 (19.5%)   21 (11.4%) 35 (21.0%)   20 (13.0%) 20 (17.2%) 1 (3.2%) 15 (29.4%)  
Ascites            
 No 249 (92.2%) 73 (89.0%) 0.370 170 (91.9%) 152 (91.0%) 0.849 143 (92.9%) 106 (91.4%) 27 (87.1%) 46 (90.2%) 0.742
 Yes 21 (7.8%) 9 (11.0%)   15 (8.1%) 15 (9.0%)   11 (7.1%) 10 (8.6%) 4 (12.9%) 5 (9.8%)  
AFP (ng/ml)
 <400 180 (66.7%) 31 (37.8%) < 0.001 129 (69.7%) 82 (49.1%) < 0.001 115 (74.7%) 65 (56.0%) 14 (45.2%) 17 (33.3%) < 0.001
  ≥ 400 90 (33.3%) 51 (62.2%)   56 (30.3%) 85 (50.9%)   39 (25.3%) 51 (44.0%) 17 (554.8%) 34 (66.7%)  
WBC (*109/L) 6.06 (4.88, 7.22) 5.40 (4.55, 6.80) 0.050 5.73 (4.66, 7.12) 6.06 (4.91, 7.16) 0.246 5.94 (4.74, 7.26) 6.17 (5.13, 7.16) 5.18 (4.55, 6.48) 5.73 (4.53, 7.31) 0.094
N% (%) 57.91 ± 9.96 57.17 ± 9.96 0.557 56.95 ± 9.87 58.61 ± 10.01 0.118 57.21 ± 9.96 58.83 ± 9.93 55.45 ± 9.42 58.09 ± 10.26 0.352
L% (%) 29.93 ± 8.47 30.05 ± 9.06 0.910 30.24 ± 8.72 29.64 ± 8.48 0.510 30.09 ± 8.49 29.72 ± 8.47 31.03 ± 9.87 29.45 ± 8.57 0.855
HB (g/L) 137.02 ± 17.20 140.01 ± 17.43 0.170 135.28 ± 17.43 140.43 ± 16.74 0.005 134.30 ± 17.08 140.64 ± 16.75 140.13 ± 18.63 139.94 ± 16.85 0.012
PLT (*109/L) 209.92 ± 77.74 198.43 ± 81.61 0.247 208.52 ± 83.84 205.82 ± 72.79 0.749 211.92 ± 85.27 207.25 ± 66.72 191.61 ± 75.35 202.57 ± 85.66 0.585
FPG (mmol/L) 4.71 (4.31, 5.22) 4.73 (4.28, 5.14) 0.792 4.76 (4.31, 5.22) 4.66 (4.30, 5.16) 0.326 4.74 (4.29, 5.22) 4.68 (4.33, 5.22) 4.84 (4.40, 5.24) 4.65 (4.23, 5.10) 0.605
PT (s) 13.09 ± 1.11 13.31 ± 1.25 0.131 13.19 ± 1.11 13.09 ± 1.19 0.435 13.17 ± 1.07 12.99 ± 1.15 13.29 ± 1.30 13.32 ± 1.24 0.280
INR 1.06 ± 0.12 1.07 ± 0.13 0.441 1.06 ± 0.12 1.06 ± 0.12 0.804 1.06 ± 0.12 1.06 ± 0.12 1.08 ± 0.14 1.07 ± 0.12 0.838
TBiL (μmol/L) 11.40 (8.38, 15.53) 11.30 (8.10, 14.83) 0.549 11.00 (8.10, 15.30) 11.60 (8.70, 15.30) 0.402 10.90 (8.10, 15.23) 11.75 (9.40, 16.58) 13.20 (8.10, 16.20) 11.20 (8.10, 13.80) 0.359
Alb (g/L) 41.08 ± 4.28 42.12 ± 4.45 0.056 41.16 ± 4.01 41.50 ± 4.48 0.453 40.91 ± 3.87 41.31 ± 4.78 42.40 ± 4.49 41.95 ± 4.47 0.220
PA (mg/L) 197.50 (156.75, 244.25) 192.00 (139.00, 247.00) 0.610 203.00 (157.00, 243.00) 191.00 (150.00, 249.00) 0.691 198.50 (157.50, 242.00) 195.50 (154.75, 255.25) 218.00 (139.00, 257.00) 180.00 (139.00, 233.00 ) 0.555
ALT (U/L) 34.50 (24.00, 47.00) 30.50 (22.00, 39.00) 0.099 33.00 (22.00, 45.50) 33.00 (24.00, 44.00) 0.936 32.50 (22.00, 46.00) 36.50 (24.25, 47.75) 34.00 (22.00, 41.00) 30.00 (22.00, 39.00) 0.196
AST (U/L) 36.00 (27.00, 49.00) 33.00 (25.50, 45.25) 0.195 33.00 (25.50, 46.00) 36.00 (29.00, 52.00) 0.032 35.00 (26.00, 47.00) 37.00 (29.00, 53.75) 29.00 (23.00, 40.00) 35.00 (28.00, 48.00) 0.047
GGT (U/L) 53.00 (33.00, 104.00) 54.00 (31.75, 91.75) 0.692 50.00 (29.00, 92.00) 57.00 (36.00, 105.00) 0.026 51.00 (30.00, 96.50) 57.00 (36.00, 109.00) 43.00 (26.00, 74.00) 57.00 (36.00, 104.00) 0.125
ALP (U/L) 63.00 (50.00, 81.00) 61.00 (45.00, 84.25) 0.638 59.00 (45.00, 78.50) 66.00 (53.00, 88.00) 0.016 59.50 (47.00, 78.00) 67.00 (55.25, 92.75) 56.00 (42.00, 85.00) 64.00 (48.00, 84.00) 0.085
MVI            
 Negative 154 (57.0%) 31 (37.8%) 0.002         
 Positive 116 (43%) 51 (62.2%)          
  1. Values are mean ± SD, n (%), or median (interquartile range), unless otherwise noted
  2. Abbreviations: AFP alpha-fetoprotein, Alb albumin, ALP alkaline phosphatase, ALT alanine aminotransferase, anti-HCV antibodies against hepatitis C virus, AST aspartate aminotransferase, BCLC Barcelona Clinic liver cancer, CK19 cytokeratin 19, FPG fasting plasma glucose, GGT γ-glutamyl transpeptidase, HB hemoglobin, HBsAg hepatitis B surface antigen, INR international normalized ratio, L% lymphocyte percentage; N% neutrophil percentage, MVI microvascular invasion, PA prealbumin, PLT blood platelets, PT prothrombin time, TBiL total bilirubin, WBC white blood cells